Cargando…
Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study
BACKGROUND: This multicenter prospective study (UMIN000019958) aimed to evaluate the usefulness of serum leucin-rich alpha-2 glycoprotein (LRG) levels in monitoring disease activity in inflammatory bowel disease (IBD). METHODS: Patients with moderate-to-severe IBD initiated on adalimumab therapy wer...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137624/ https://www.ncbi.nlm.nih.gov/pubmed/33942166 http://dx.doi.org/10.1007/s00535-021-01793-0 |
_version_ | 1783695649640808448 |
---|---|
author | Shinzaki, Shinichiro Matsuoka, Katsuyoshi Tanaka, Hiroki Takeshima, Fuminao Kato, Shingo Torisu, Takehiro Ohta, Yuki Watanabe, Kenji Nakamura, Shiro Yoshimura, Naoki Kobayashi, Taku Shiotani, Akiko Hirai, Fumihito Hiraoka, Sakiko Watanabe, Mamoru Matsuura, Minoru Nishimoto, Shohei Mizuno, Shinta Iijima, Hideki Takehara, Tetsuo Naka, Tetsuji Kanai, Takanori Matsumoto, Takayuki |
author_facet | Shinzaki, Shinichiro Matsuoka, Katsuyoshi Tanaka, Hiroki Takeshima, Fuminao Kato, Shingo Torisu, Takehiro Ohta, Yuki Watanabe, Kenji Nakamura, Shiro Yoshimura, Naoki Kobayashi, Taku Shiotani, Akiko Hirai, Fumihito Hiraoka, Sakiko Watanabe, Mamoru Matsuura, Minoru Nishimoto, Shohei Mizuno, Shinta Iijima, Hideki Takehara, Tetsuo Naka, Tetsuji Kanai, Takanori Matsumoto, Takayuki |
author_sort | Shinzaki, Shinichiro |
collection | PubMed |
description | BACKGROUND: This multicenter prospective study (UMIN000019958) aimed to evaluate the usefulness of serum leucin-rich alpha-2 glycoprotein (LRG) levels in monitoring disease activity in inflammatory bowel disease (IBD). METHODS: Patients with moderate-to-severe IBD initiated on adalimumab therapy were enrolled herein. Serum LRG, C-reactive protein (CRP), and fecal calprotectin (fCal) levels were measured at week 0, 12, 24, and 52. Colonoscopy was performed at week 0, 12, and 52 for ulcerative colitis (UC), and at week 0, 24, and 52 for Crohn’s disease (CD). Endoscopic activity was assessed using the Simple Endoscopic Score for Crohn’s Disease (SES-CD) for CD and the Mayo endoscopic subscore (MES) for UC. RESULTS: A total of 81 patients was enrolled. Serum LRG levels decreased along with improvements in clinical and endoscopic outcomes upon adalimumab treatment (27.4 ± 12.6 μg/ml at week 0, 15.5 ± 7.7 μg/ml at week 12, 15.7 ± 9.6 μg/ml at week 24, and 14.5 ± 6.8 μg/ml at week 52), being correlated with endoscopic activity at each time point (SES-CD: r = 0.391 at week 0, r = 0.563 at week 24, r = 0.697 at week 52; MES: r = 0.534 at week 0, r = 0.429 at week 12, r = 0.335 at week 52). Endoscopic activity better correlated with LRG compared to CRP and fCal on pooled analysis at all time points (SES-CD: LRG: r = 0.636, CRP: r = 0.402, fCal: r = 0.435; MES: LRG: r = 0.568, CRP: 0.389, fCal: r = 0.426). CONCLUSIONS: Serum LRG is a useful biomarker of endoscopic activity both in CD and UC during the adalimumab treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00535-021-01793-0. |
format | Online Article Text |
id | pubmed-8137624 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-81376242021-06-03 Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study Shinzaki, Shinichiro Matsuoka, Katsuyoshi Tanaka, Hiroki Takeshima, Fuminao Kato, Shingo Torisu, Takehiro Ohta, Yuki Watanabe, Kenji Nakamura, Shiro Yoshimura, Naoki Kobayashi, Taku Shiotani, Akiko Hirai, Fumihito Hiraoka, Sakiko Watanabe, Mamoru Matsuura, Minoru Nishimoto, Shohei Mizuno, Shinta Iijima, Hideki Takehara, Tetsuo Naka, Tetsuji Kanai, Takanori Matsumoto, Takayuki J Gastroenterol Original Article—Alimentary Tract BACKGROUND: This multicenter prospective study (UMIN000019958) aimed to evaluate the usefulness of serum leucin-rich alpha-2 glycoprotein (LRG) levels in monitoring disease activity in inflammatory bowel disease (IBD). METHODS: Patients with moderate-to-severe IBD initiated on adalimumab therapy were enrolled herein. Serum LRG, C-reactive protein (CRP), and fecal calprotectin (fCal) levels were measured at week 0, 12, 24, and 52. Colonoscopy was performed at week 0, 12, and 52 for ulcerative colitis (UC), and at week 0, 24, and 52 for Crohn’s disease (CD). Endoscopic activity was assessed using the Simple Endoscopic Score for Crohn’s Disease (SES-CD) for CD and the Mayo endoscopic subscore (MES) for UC. RESULTS: A total of 81 patients was enrolled. Serum LRG levels decreased along with improvements in clinical and endoscopic outcomes upon adalimumab treatment (27.4 ± 12.6 μg/ml at week 0, 15.5 ± 7.7 μg/ml at week 12, 15.7 ± 9.6 μg/ml at week 24, and 14.5 ± 6.8 μg/ml at week 52), being correlated with endoscopic activity at each time point (SES-CD: r = 0.391 at week 0, r = 0.563 at week 24, r = 0.697 at week 52; MES: r = 0.534 at week 0, r = 0.429 at week 12, r = 0.335 at week 52). Endoscopic activity better correlated with LRG compared to CRP and fCal on pooled analysis at all time points (SES-CD: LRG: r = 0.636, CRP: r = 0.402, fCal: r = 0.435; MES: LRG: r = 0.568, CRP: 0.389, fCal: r = 0.426). CONCLUSIONS: Serum LRG is a useful biomarker of endoscopic activity both in CD and UC during the adalimumab treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00535-021-01793-0. Springer Singapore 2021-05-03 2021 /pmc/articles/PMC8137624/ /pubmed/33942166 http://dx.doi.org/10.1007/s00535-021-01793-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article—Alimentary Tract Shinzaki, Shinichiro Matsuoka, Katsuyoshi Tanaka, Hiroki Takeshima, Fuminao Kato, Shingo Torisu, Takehiro Ohta, Yuki Watanabe, Kenji Nakamura, Shiro Yoshimura, Naoki Kobayashi, Taku Shiotani, Akiko Hirai, Fumihito Hiraoka, Sakiko Watanabe, Mamoru Matsuura, Minoru Nishimoto, Shohei Mizuno, Shinta Iijima, Hideki Takehara, Tetsuo Naka, Tetsuji Kanai, Takanori Matsumoto, Takayuki Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study |
title | Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study |
title_full | Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study |
title_fullStr | Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study |
title_full_unstemmed | Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study |
title_short | Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study |
title_sort | leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: planet study |
topic | Original Article—Alimentary Tract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137624/ https://www.ncbi.nlm.nih.gov/pubmed/33942166 http://dx.doi.org/10.1007/s00535-021-01793-0 |
work_keys_str_mv | AT shinzakishinichiro leucinerichalpha2glycoproteinisapotentialbiomarkertomonitordiseaseactivityininflammatoryboweldiseasereceivingadalimumabplanetstudy AT matsuokakatsuyoshi leucinerichalpha2glycoproteinisapotentialbiomarkertomonitordiseaseactivityininflammatoryboweldiseasereceivingadalimumabplanetstudy AT tanakahiroki leucinerichalpha2glycoproteinisapotentialbiomarkertomonitordiseaseactivityininflammatoryboweldiseasereceivingadalimumabplanetstudy AT takeshimafuminao leucinerichalpha2glycoproteinisapotentialbiomarkertomonitordiseaseactivityininflammatoryboweldiseasereceivingadalimumabplanetstudy AT katoshingo leucinerichalpha2glycoproteinisapotentialbiomarkertomonitordiseaseactivityininflammatoryboweldiseasereceivingadalimumabplanetstudy AT torisutakehiro leucinerichalpha2glycoproteinisapotentialbiomarkertomonitordiseaseactivityininflammatoryboweldiseasereceivingadalimumabplanetstudy AT ohtayuki leucinerichalpha2glycoproteinisapotentialbiomarkertomonitordiseaseactivityininflammatoryboweldiseasereceivingadalimumabplanetstudy AT watanabekenji leucinerichalpha2glycoproteinisapotentialbiomarkertomonitordiseaseactivityininflammatoryboweldiseasereceivingadalimumabplanetstudy AT nakamurashiro leucinerichalpha2glycoproteinisapotentialbiomarkertomonitordiseaseactivityininflammatoryboweldiseasereceivingadalimumabplanetstudy AT yoshimuranaoki leucinerichalpha2glycoproteinisapotentialbiomarkertomonitordiseaseactivityininflammatoryboweldiseasereceivingadalimumabplanetstudy AT kobayashitaku leucinerichalpha2glycoproteinisapotentialbiomarkertomonitordiseaseactivityininflammatoryboweldiseasereceivingadalimumabplanetstudy AT shiotaniakiko leucinerichalpha2glycoproteinisapotentialbiomarkertomonitordiseaseactivityininflammatoryboweldiseasereceivingadalimumabplanetstudy AT hiraifumihito leucinerichalpha2glycoproteinisapotentialbiomarkertomonitordiseaseactivityininflammatoryboweldiseasereceivingadalimumabplanetstudy AT hiraokasakiko leucinerichalpha2glycoproteinisapotentialbiomarkertomonitordiseaseactivityininflammatoryboweldiseasereceivingadalimumabplanetstudy AT watanabemamoru leucinerichalpha2glycoproteinisapotentialbiomarkertomonitordiseaseactivityininflammatoryboweldiseasereceivingadalimumabplanetstudy AT matsuuraminoru leucinerichalpha2glycoproteinisapotentialbiomarkertomonitordiseaseactivityininflammatoryboweldiseasereceivingadalimumabplanetstudy AT nishimotoshohei leucinerichalpha2glycoproteinisapotentialbiomarkertomonitordiseaseactivityininflammatoryboweldiseasereceivingadalimumabplanetstudy AT mizunoshinta leucinerichalpha2glycoproteinisapotentialbiomarkertomonitordiseaseactivityininflammatoryboweldiseasereceivingadalimumabplanetstudy AT iijimahideki leucinerichalpha2glycoproteinisapotentialbiomarkertomonitordiseaseactivityininflammatoryboweldiseasereceivingadalimumabplanetstudy AT takeharatetsuo leucinerichalpha2glycoproteinisapotentialbiomarkertomonitordiseaseactivityininflammatoryboweldiseasereceivingadalimumabplanetstudy AT nakatetsuji leucinerichalpha2glycoproteinisapotentialbiomarkertomonitordiseaseactivityininflammatoryboweldiseasereceivingadalimumabplanetstudy AT kanaitakanori leucinerichalpha2glycoproteinisapotentialbiomarkertomonitordiseaseactivityininflammatoryboweldiseasereceivingadalimumabplanetstudy AT matsumototakayuki leucinerichalpha2glycoproteinisapotentialbiomarkertomonitordiseaseactivityininflammatoryboweldiseasereceivingadalimumabplanetstudy |